Impact of cytochrome P450 2C19*2 polymorphism on the clinical cardiovascular events after stent implantation in patients receiving clopidogrel of a southern Tunisian region

Leila Abid, Lobna Laroussi, Amine Bahloul, Ahmed Siala, R. Abdelhédi, Najla Kharrat, Mourad Hentati, Samir Kammoun

Cardiology Department, Hedi Chaker Hospital, Medicine University of Sfax, Sfax, Tunisia.
CBS Center, Sfax, Tunisia.

DOI: 10.4236/wjcd.2013.31002                

Abstract

Introduction: The concept of clopidogrel resistance, first described in biology is being strengthened by recent data from clinical epidemiology. The cardiologists have been sensitized to this concept because of its possible involvement in the occurrence of coronary stent thrombosis. Purpose of the study: The purpose of this study was to investigate the genetic variant of the gene CYP 2C19 inour population and to assess the involvement of this genetic profile in the occurrence of major cardiovascular events (MACE) during the follow-up period. Methods: Our prospective study was conducted between May 2009 and September 2010 including 100 patients admitted to the cardiology department for percutaneous coronary stenting. The patients were divided into 2 groups: those with at least one CYP2C19*2 allele (*2 carriers) and non-carriers. Results: The mean age of our patients was 56.7 years ± 10, 5. No remarkable differences in the baseline characteristics were noted between the two groups. The prevalence of CYP2C19*2 allele in our population was 11.5%. Hospital mortality was estimated at 3%. No statistically significant differences were noted between the two groups regarding the occurrence of intra hospital MACE. The mean follow up was 7.5 ± 4.87 months for the entire study population. The rate of MACE during the follow-up of patients receiving clopidogrel was 8.2% throughout the study population: 5.3% in the *2 non-carriers versus 18.2% in the *2 carriers with a statistically significant difference (p = 0.075) at the risk of error of 10%. Concerning the occurrence of stent thrombosis, there was no significant statistical difference between the two study groups. Conclusion: From these results it is suggested that CYP2C19*2 polymorphism is associated with increase in the occurrence of MACE among Tunisian patients receiving clopidogrel. A larger study is needed to assess the role of genotyping in the evaluation of the phenomenon of clopidogrel resistance.

Keywords

Clopidogrel; CYP2C19*2 Polymorphism; MACE; Stent Thrombus; Percutaneous Coronary Intervention

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Mehta, S.R., Yusuf, S., Peters, R.J., Bertrand, M.E., Lewis, B.S., Natarajan, M.K., et al. (2001) Effects of pre-treatment with clopidogrel and aspirin followed by long- term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. The Lancet, 358, 527-533. doi:10.1016/S0140-6736(01)05701-4
[2]	Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., Al-fonso, F., Macaya, C., Bass, T.A., et al. (2007) Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. Journal of the American College of Cardiology, 49, 1505- 1516. doi:10.1016/j.jacc.2006.11.044
[3]	Wang, T.H., Bhatt, D.L. and Topol, E.J. (2006) Aspirin and clopidogrel resistance: An emerging clinical entity. European Heart Journal, 27, 647-654. doi:10.1093/eurheartj/ehi684
[4]	Oh, I.Y., Park, K.W., Kang, S.H., Park, J.J., Na, S.H., Kang, H.J., et al. (2012) Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart, 98, 139-144. doi:10.1136/hrt.2011.227272
[5]	Gurbel, P.A. and Tantry, U.S. (2007) Clopidogrel resis- tance? Thrombosis Research, 120, 311-321. doi:10.1016/j.thromres.2006.08.012
[6]	Savi, P., Pereillo, J.M., Uzabiaga, M.F., Combalbert, J., Picard, C., Maffrand, J.P., et al. (2000) Identification and biological activity of the active metabolite of clopidogrel. Thrombosis and Haemostasis, 84, 891-896.
[7]	Mauri, L., Hsieh, W.H., Massaro, J.M., Ho, K.K., D’Ago-stino, R. and Cutlip, D.E. (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. The New England Journal of Medicine, 356, 1020-1029. doi:10.1056/NEJMoa067731
[8]	Chaudhry, A.S., Kochhar, R. and Kohli, K.K. (2009) Importance of CYP2C19 genetic polymorphism in the eradication of Helicobacter pylori in north Indians. Indian Journal of Medical Research, 130, 437-443.
[9]	Geisler, T., Langer, H., Wydymus, M., G?hring, K., Zürn, C. and Bigalke, B. (2006) Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. European Heart Journal, 27, 2420-2425. doi:10.1093/eurheartj/ehl275
[10]	Hochholzer, W., Trenk, D., Bestehorn, H.P., Fischer, B., Valina, C.M. and Ferenc, M. (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrelon early clinical outcome of elective coronary stent placement. Journal of the American College of Cardiology, 48, 1742-1750. doi:10.1016/j.jacc.2006.06.065
[11]	Lev, E.I., Patel, R.T., Maresh, K.J., Guthikonda, S., Granada, J., DeLao, T. and Bray, P.F., (2006) Aspirin and clopidogrel drug response in patients undergoing percu-taneous coronary intervention: The role of dual drug resistance. Journal of the American College of Cardiology, 47, 27-33. doi:10.1016/j.jacc.2005.08.058
[12]	Gurbel, P.A., Bliden, K.P., Hayes, K.M., Yoho, J.A., Herzog, W.R. and Tantry, U.S. (2005) The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. Journal of the American College of Cardiology, 45, 1392-1396. doi:10.1016/j.jacc.2005.01.030
[13]	Dziewierz, A., Dudek, D., Heba, G., Rakowski, T., Mielecki, W. and Dubiel, J.S. (2005) Interindividualvari-ability in response to clopidogrel in patients with coronary artery disease. Kardiologia Polska, 62, 108-117.
[14]	Serebruany, V.L., Steinhubl, S.R., Berger, P.B., Malinin, A.I., Bhatt, D.L. and Topol, E.J. (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. Journal of the American College of Cardiology, 45, 246-251. doi:10.1016/j.jacc.2004.09.067
[15]	Michelson, A.D., Linden, M.D., Furman, M.I., Li, Y., Barnard, M.R., Fox, M.L., et al. (2007) Evidence that preexistent variability in platelet response to ADP accounts for “clopidogrel resistance”. Journal of Thrombo-sis and Haemostasis, 5, 75-81. doi:10.1111/j.1538-7836.2006.02234.x
[16]	Xie, H.G., Stein, C.M., Kim, R.B., Wilkinson, G.R., Flockhart, D.A. and Wood, A.J. (1999) Allelic, genotypic and phenotypic distributions of S-mephenytoin 4’-hydro- xylase (CYP2C19)in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics, 9, 539-549. doi:10.1097/00008571-199910000-00001
[17]	Goldstein, J.A., Ishizaki, T., Chiba, K., Morais, S.M., Bell, D., Krahn, P.M., et al. (1997) Frequencies of the defective CYP2C19 alleles responsible for the mepheny- toin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 1, 59-64. doi:10.1097/00008571-199702000-00008
[18]	Takakubo, F., Kuwano, A. and Kondo, I. (1996) Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Pharmacogenetics, 6, 265-267. doi:10.1097/00008571-199606000-00011
[19]	Nowak, M.P., Sellers, E.M. and Tyndale, R.F. (1998) Canadian native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clinical Pharmacology & Therapeutics, 64, 378-383. doi:10.1016/S0009-9236(98)90068-6
[20]	Ruas, J.L. and Lechner, M.C. (1997) Allele frequency of CYP2C19 in a Portuguese population. Pharmacogenetics, 7, 333-335. doi:10.1097/00008571-199708000-00009
[21]	Chang, M., Dahl, M.L., Tybring, G., Tharson, E. and Bertilsson, L. (1995) Use of omeprazole as aprobe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics, 5, 358-363. doi:10.1097/00008571-199512000-00004
[22]	Collet, J.P., Hulot, J.S., Pena, A., Villard, E., Esteve, J.B., Silvain, J., et al. (2009) CytochromeP450 2C19 poly-morphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet, 373, 309-317. doi:10.1016/S0140-6736(08)61845-0
[23]	Schuldiner, A.R., O’Connell, J.R., Bliden, K.P., Gandhi, A., Ryan, K., Horenstein, R.B., et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect andclinical efficacy of clopidogrel. The Journal of the American Medical Association, 302, 849-857. doi:10.1001/jama.2009.1232
[24]	Sibbing, D., Stegherr, J., Latz, W., Koch, W., Mehilli, J., Dorrler, K., et al. (2009) Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. European Heart Jour- nal, 30, 916-922. doi:10.1093/eurheartj/ehp041
[25]	Mega, J.L., Close, S.L., Wiviott, S.D., Wiviott, S.D., Shen, L., Hockett, R.D., et al. (2009) Cytochrome P450 polymorphism and response to clopidogrel. The New England Journal of Medicine, 360, 354-362. doi:10.1056/NEJMoa0809171
[26]	Trenk, D., Hochholzer, W., Fromm, M.F., Chialda, L.E., Pahi, A., Valina, C.M., et al. (2008) Cytochrome P450 2C19 681G>A polymorphism and high onclopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. Journal of the American College of Cardiology, 51, 1925-1934. doi:10.1016/j.jacc.2007.12.056
[27]	Jinnai, T., Horiuchi, H., Makiyama, T., Tazaki, J., Tada, T., Akao, M., et al. (2009) Impact of CYP2C19 polymorphism on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circulation Journal, 73, 1498-1503. doi:10.1253/circj.CJ-09-0019